|137.48||-2.28||-1.63%||Vol 11.05M||1Y Perf 1.95%|
|Apr 7th, 2020 16:02|
|-0.05 -0.04%||- -%|
|Target Price||158.15||Analyst Rating||Moderate Buy 1.56|
|Potential %||15.03||Finscreener Ranking||★+ 43.42|
|Insiders Trans % 3/6/12 mo.||-50/-43/-25||Value Ranking||★+ 46.55|
|Insiders Value % 3/6/12 mo.||-99/-94/-90||Growth Ranking||★★★+ 55.38|
|Insiders Shares Cnt. % 3/6/12 mo.||-99/-93/-90||Income Ranking||★★ 43.26|
|Market Cap||362.45B||Earnings Rating||Sell|
|Price Range Ratio 52W %||62.46||Earnings Date||14th Apr 2020|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
Return on Equity (5Y Avg)
ROE last 12 Months
Return on Assets (5Y Avg)
ROA last 12 Months
Return on Capital (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||14th Apr 2020|
|Estimated EPS Next Report||2.11|
|EPS Growth Next 5 Years %||6.30|
|Avg. Weekly Volume||11.63M|
|Avg. Monthly Volume||16.41M|
|Avg. Quarterly Volume||10.88M|
Johnson & Johnson (NYSE: JNJ) closed at 139.76 per share at the end of the most recent trading day (a 4.17% change compared to the prior day closing price) with a volume of 14.99M shares and market capitalization of 362.45B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indexes and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 135100 people. Johnson & Johnson CEO is Alex Gorsky.
The one-year performance of Johnson & Johnson stock is 1.95%, while year-to-date (YTD) performance is -4.19%. JNJ stock has a five-year performance of 42.76%. Its 52-week range is between 109.16 and 154.5, which gives JNJ stock a 52-week price range ratio of 62.46%
Johnson & Johnson currently has a PE ratio of 23.80, a price-to-book (PB) ratio of 5.95, a price-to-sale (PS) ratio of 5.94, a price to cashflow ratio of 15.40, a PEG ratio of 2.32, a ROA of 9.65%, a ROC of 17.01% and a ROE of 25.15%. The company’s profit margin is 18.32%, its EBITDA margin is 30.00%, and its revenue ttm is $62.04 Billion , which makes it $23.53 revenue per share.
Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.11 for the next earnings report. Johnson & Johnson’s next earnings report date is 14th Apr 2020.
The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (1.56), with a target price of $158.15, which is +15.03% compared to the current price. The earnings rating for Johnson & Johnson stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Johnson & Johnson has a dividend yield of 2.72% with a dividend per share of $3.80 and a payout ratio of 70.00%.
Johnson & Johnson has a Buy technical analysis rating based on Technical Indicators (ADX : 29.26, ATR14 : 6.83, CCI20 : 126.72, Chaikin Money Flow : 0.12, MACD : -1.54, Money Flow Index : 60.17, ROC : 16.47, RSI : 55.14, STOCH (14,3) : 96.20, STOCH RSI : 1.00, UO : 62.48, Williams %R : -3.80), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Alex Gorsky (Option Excercise at a value of $0), Ashley McEvoy (Option Excercise at a value of $0), Hubert Joly (Buy at a value of $706 399), Jennifer L. Taubert (Option Excercise at a value of $0), Joaquin Duato (Option Excercise at a value of $0), Joseph J. Wolk (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $126 305), Kathryn E. Wengel (Sold 2 017 shares of value $284 538 ), Kathy Wengel (Option Excercise at a value of $126 305), Kathy Wengel (Sold 2 017 shares of value $284 538 ), Marillyn A. Hewson (Buy at a value of $419 040), Michael E. Sneed (Option Excercise at a value of $3 639 975), Michael E. Sneed (Sold 58 128 shares of value $8 683 568 ), Michael H. Ullmann (Option Excercise at a value of $0), Michael Sneed (Option Excercise at a value of $3 639 975), Michael Sneed (Sold 58 128 shares of value $8 683 568 ), Paulus Stoffels (Option Excercise at a value of $0), Peter M. Fasolo (Option Excercise at a value of $0), Robert J. Decker (Option Excercise at a value of $0), Thibaut Mongon (Option Excercise at a value of $1 738 618), Thibaut Mongon (Sold 39 224 shares of value $5 803 583 ), William D. Perez (Buy at a value of $63 843)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.